BVX — Bivictrix Therapeutics Income Statement
0.000.00%
Last trade - 00:00- £6.19m
- £4.70m
Annual income statement for Bivictrix Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | Interim Report | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.49 | 1.89 | 2.98 | 3.02 |
| Operating Profit | -0.49 | -1.89 | -2.98 | -3.02 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -0.509 | -2.53 | -2.97 | -3 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.425 | -2.34 | -2.5 | -2.54 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.425 | -2.34 | -2.5 | -2.54 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.425 | -2.34 | -2.5 | -2.54 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.006 | -0.054 | -0.038 | -0.035 |
| Dividends per Share |